Brian Markison, Osmotica is very well positioned to compete on analytics. The four pillars of analytics: distinctive capability, enterprise-wide analytics, senior management commitment, and large-scale ambition. Vertical Pharmaceuticals (“Vertical”), like other pharmaceutical companies, is using data science for a variety of reasons; in R&D to reduce the tremendous costs associated with creating new products, to incorporate in-process controls for quality, to manage storage and distribution, to improve efficiencies and to ultimately increase both their market share and profit margins, all while adhering to strict government controls. Based on my short time working at Vertical it is very clear that compliance is a distinct capability/top priority at Vertical Pharmaceuticals, LLC. The company website reinforces my first impressions and boasts that “Vertical is committed to establishing and maintaining an effective compliance program in accordance with “Compliance Program Guidance for Pharmaceutical Manufacturers,” published by the Office of Inspector General, U.S. Department of Health and Human Services (the “HHS-OIG Guidance”). Our Compliance Program is one of the key components of our commitment to the highest standards of corporate conduct.” (Program Overview, 2015) At Vertical, analytics is an enterprise level strategy that can be found across all departments, teams and functions. Data accuracy is paramount at Vertical because faulty data or incorrect analysis can, not
Prescription drug prices are increasing and it is becoming much more difficult for people that rely on healthcare to purchase them. Branded prescription drugs, specialty prescription drugs, and even generic products like ibuprofen have been inflating in the last 7 years. There are a number of reasons to attribute to the said inflation over the last 7 years. Newly approved branded and specialty prescription drugs and the rising costs of existing branded and specialty prescription drugs.
It all started with one sentence. "Take a look at this pamphlet" my friend told me 5 years ago. That's just what I did, not knowing that the pamphlet would change my life for the better. My life at that particular moment was spiraling out of control. Four years in an abusive relationship took a toll on me. Four years of mental anguish drained my confidence and threw me into extreme depression which resulted in me failing numerous classes and then academic dismissal. At that moment I was at my lowest and my friend saw that. She handed me a pamphlet for Kingsborough Community College continuing education courses hoping to jog my interest and to get me away from my abuser.
The Center for Disease Control has some of the most accurate information regarding the illnesses that exist in the United States because of their extensive testing and access to studies done by researchers and scientists. So when they state that there are thousands of toddlers and small children currently taking psychotropic medications, this information is shocking, but true. Children that would normally never be considered good candidates for this kind of treatment are being handed fistfuls of prescription pills that do more harm than good. And all for the sake of their education. This article will discuss some of the main points that experts attribute to this problem.
All these trends can be fine and wonderful, but they have the potential to become scary and dangerous. It can diminish the value of the pharmacist or the technicians that work in the pharmacy. It has the potential to get rid of the pharmacist altogether. With the system doing that a lot of possible drug errors can happen, due to no one being there to check if the correct information is being put in
On December 13, 2012, Vertical Pharmaceuticals Inc., a privately owned company that sells niche prescription drugs geared toward women’s health and pain management, and an affiliated company sued Deloitte & Touche LLP in New Jersey state court for alleged accountant malpractice. Deloitte’s false accusation led to the withdrawal of another public company's planned acquisition of Vertical. If the deal completed, Vertical would be extremely beneficial from the acquisition because the public company would help its business and would achieve generous profits of $500 million or more. According to the complaint, Deloitte discontinued the audit of Vertical and Trigen Laboratories financial statement for 2011 and then resigned from the
* Centralization will provide a consistent flow of information across the organization and the affiliates and better structure and control to this fast growing organization.
The book is all about the things that make one to be a smart consumer of cutting-edge analytics, facilitating to frame the judgement, questioning about the information and the procedure, operating to comprehend the consequences, and using them to progress results for his or her business. Even though it sounds direct, I directly acknowledged it as a deceptively single-minded set of purposes of the book. The writers planned the first half of the book about an analytics outline that entails of six stages: problem acknowledgment, evaluation of previous results, displaying, data assortment and data examination, and outcomes demonstration and action. This planned method to discerning about analytics is one of the most important notions that Davenport
I agree that it is permissible for every corporation to utilize big data and analytics to gain a competitive advantage, but under strict rules and guidelines to protect
The foremost concern the Pharm Universe management has is its’ desire to transform the organization into a multi-product company that would be able to compete in a global scale. The company has had a patented discovery and marketing of an effective blood clotting drug and they have been intent on developing new formulas for medications that would strengthen resistance against bacterial infections and reduce memory loss for the elderly. The pressure is on, though, for the unit members to come up with new and viable formulas that would put Pharm Universe ahead of the pharmaceutical competition. Failure to do so would mean dire consequences for the management team, even worse, termination from the company. Organizational issues can be rooted upon
The software, hardware, and computing equipment used to manage CDER’s drug related information is not without cost. With our help, CDER develops the business case, the funding profile, and the performance measures that Congress will used to judge the effectiveness of CDER’s IT spending. Before Vergys provided support to FDA, CDER was barely reporting 60% of its IT expenditures – with some systems not being accounted for properly or not accounted for at all. This oversight had the potential to compromise CDER’s overall funding. Currently 100% of every IT budget dollar is accounted for and
When implementing systems, the projects are IT driven, business is consulted late and functionality is not a priority. Unfortunately Gilead is a great case study of what not to due when considering corporate business intelligence programs. Business Intelligence means “leveraging information assets with key business processes to achieve improved business performance. It involves business information and analysis that is used within the context of a key business process, supports decisions and actions and leads to improved business performance” (Williams, S. & Williams, N.,2010). For this to work, business processes must be in place and supported by management; not the case for
Porter’s Five Competitive Forces Analysis is a framework developed by Michael E. Porter of Harvard Business School for study of industry analysis by analyzing five competitive forces which define industry and its business strategy. These five competitive forces determine the competitive advantages, disadvantages and attractiveness or profitability of industry.
Healthcare industry generates large volumes of clinically related data every minute. It can be in the form of electronic records, scan reports, printed documents, images etcetera. The sources of these records are technologies like CT scan, MRI scan, Ultrasound, ECG, Dialysis, biopsy equipment etc. The objectives of this smart approach are to make this data useful and productive for analysis and study of health patterns and create statistics. A detailed analysis can help the community to get awareness for improved nutrition and hygiene.
Pfizer’s compliance program is designed to support legal and conduct throughout the Company. The Chief Compliance and Risk Officer oversees
Today’s drug discovery process consists of a methodical and multi-faceted approach, where it takes many years for a drug to reach the market. It is said that the entire drug